Drugs / ADP-A2AFP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03132792 | May 2017 → Jul 2021 | hepatocellular carcinoma | Adaptimmune | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADP-A2AFP | “ADP-A2AFP is an investigational autologous T-cell therapy with an affinity-enhanced T-cell receptor (TCR) targeting alpha-fetoprotein (AFP).” PMID 40812667 ↗ Aug 2025 |
| Modality | Cell therapy | “ADP-A2AFP is an investigational autologous T-cell therapy” PMID 40812667 ↗ Aug 2025 |
| Route | Intravenous | “followed by ADP-A2AFP intravenous infusion” PMID 40812667 ↗ Aug 2025 |